Identification

Name
Brimonidine
Accession Number
DB00484  (APRD00034)
Type
Small Molecule
Groups
Approved
Description

Brimonidine is a drug used to treat glaucoma. It acts via decreasing aqueous humor synthesis. [Wikipedia] A topical gel formulation, marketed under the name Mirvaso, was FDA approved on August 2013 for the treatment of rosacea.

Structure
Thumb
Synonyms
  • 5-Bromo-6-(2-imidazolin-2-ylamino)quinoxaline
  • Brimonidina
  • Brimonidine
  • Brimonidinum
  • Bromoxidine
External IDs
AGN-190342 / UK-14304
Product Ingredients
IngredientUNIICASInChI Key
Brimonidine Tartrate4S9CL2DY2H70359-46-5QZHBYNSSDLTCRG-LREBCSMRSA-N
Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
AlphaganLiquid0.2 %OphthalmicAllergan1997-12-02Not applicableCanada
Alphagan PSolution / drops1 mg/mLOphthalmicPhysicians Total Care, Inc.2013-03-08Not applicableUs
Alphagan PSolution0.15 %OphthalmicAllergan2003-11-05Not applicableCanada
Alphagan PSolution / drops1.5 mg/mLOphthalmicAllergan2001-07-10Not applicableUs
Alphagan PSolution / drops1.5 mg/mLOphthalmicPhysicians Total Care, Inc.2002-10-16Not applicableUs
Alphagan PSolution / drops1 mg/mLOphthalmicAllergan2006-01-25Not applicableUs
BrimonidineSolution0.2 %OphthalmicPharmascience IncNot applicableNot applicableCanada
Brimonidine OphthalmicSolution0.2 %OphthalmicPharmel IncNot applicableNot applicableCanada
Brimonidine PSolution0.15 %OphthalmicAa Pharma Inc2008-07-15Not applicableCanada
Brimonidine TartrateSolution1.5 mg/mLOphthalmicPhysicians Total Care, Inc.2009-12-22Not applicableUs
Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Apo-brimonidineSolution0.2 %OphthalmicApotex Corporation2005-06-02Not applicableCanada
BrimonidineSolution / drops2 mg/mLOphthalmicA S Medication Solutions2006-09-07Not applicableUs
BrimonidineSolution / drops2 mg/mLOphthalmicAkorn2006-09-07Not applicableUs
Brimonidine TartrateSolution / drops2 mg/mgOphthalmicOsmotica Pharmaceutical Corp.2015-01-01Not applicableUs
Brimonidine TartrateSolution / drops2 mg/mLOphthalmicPhysicians Total Care, Inc.2011-07-25Not applicableUs
Brimonidine TartrateSolution / drops2 mg/mLOphthalmicStat Rx USA2003-05-28Not applicableUs
Brimonidine TartrateSolution / drops2 mg/mLOphthalmicA S Medication Solutions2003-05-282017-06-20Us
Brimonidine TartrateSolution / drops2 mg/mLOphthalmicRemedy Repack2013-06-242017-01-07Us
Brimonidine TartrateSolution / drops2 mg/mLOphthalmicBauch & Lomb Incorporated2003-05-28Not applicableUs
Brimonidine TartrateSolution / drops2 mg/mLOphthalmicRegimed Medical2016-01-05Not applicableUs
Mixture Products
NameIngredientsDosageRouteLabellerMarketing StartMarketing End
Apo-brimonidine-timopBrimonidine Tartrate (0.2 %) + Timolol (0.5 %)SolutionOphthalmicApotex CorporationNot applicableNot applicableCanada
CombiganBrimonidine Tartrate (2 mg/mL) + Timolol maleate (5 mg/mL)Solution / dropsOphthalmicPhysicians Total Care, Inc.2011-08-29Not applicableUs
CombiganBrimonidine Tartrate (0.2 %) + Timolol (0.5 %)SolutionOphthalmicAllergan2003-12-11Not applicableCanada
CombiganBrimonidine Tartrate (2 mg/mL) + Timolol maleate (5 mg/mL)Solution / dropsOphthalmicAllergan2007-11-14Not applicableUs
SimbrinzaBrimonidine Tartrate (0.2 %) + Brinzolamide (1 %)SuspensionOphthalmicNovartis2015-02-17Not applicableCanada
SimbrinzaBrimonidine Tartrate (2 mg/mL) + Brinzolamide (10 mg/mL)Suspension / dropsOphthalmicAlcon, Inc.2013-05-01Not applicableUs
SimbrinzaBrimonidine Tartrate (2 mg/ml) + Brinzolamide (10 mg/ml)Suspension / dropsOphthalmicAlcon, Inc.2014-07-18Not applicableEu
SimbrinzaBrimonidine Tartrate (2 mg/ml) + Brinzolamide (10 mg/ml)Suspension / dropsOphthalmicAlcon, Inc.2014-07-18Not applicableEu
Categories
UNII
E6GNX3HHTE
CAS number
59803-98-4
Weight
Average: 292.135
Monoisotopic: 291.011957992
Chemical Formula
C11H10BrN5
InChI Key
XYLJNLCSTIOKRM-UHFFFAOYSA-N
InChI
InChI=1S/C11H10BrN5/c12-9-7(17-11-15-5-6-16-11)1-2-8-10(9)14-4-3-13-8/h1-4H,5-6H2,(H2,15,16,17)
IUPAC Name
5-bromo-N-(4,5-dihydro-1H-imidazol-2-yl)quinoxalin-6-amine
SMILES
BrC1=C(NC2=NCCN2)C=CC2=NC=CN=C12

Pharmacology

Indication

The ophthalmic solution is indicated for patients with open-angle glaucoma or ocular hypertension to lower intraocular pressure. The topical gel is indicated for the treatment of persistent (nontransient) facial erythema of rosacea in adults 18 years or older.

Structured Indications
Pharmacodynamics

Brimonidine significantly lowers intraocular pressure with minimal effects on cardiovascular and pulmonary parameters. It lowers intraocular pressure by reducing aqueous humor production and increasing uveoscleral outflow.

Mechanism of action

Brimonidine is an alpha adrenergic receptor agonist (primarily alpha-2). It has a peak ocular hypotensive effect occurring at two hours post-dosing. Fluorophotometric studies in animals and humans suggest that Brimonidine has a dual mechanism of action by reducing aqueous humor production and increasing uveoscleral outflow. The topical gel reduces erythema through direct vasocontriction.

TargetActionsOrganism
AAlpha-2A adrenergic receptor
agonist
Human
AAlpha-2B adrenergic receptor
agonist
Human
AAlpha-2C adrenergic receptor
agonist
Human
Absorption

Minimal systemic absorption occurs after ocular insertion. When the topical gel was applied to adult patients with facial erythema associated with rosacea, the plasma maximum concentration (Cmax) and area under the concentration-time curve (AUC) were 46 ± 62 pg/mL and 417 ± 264 pg.hr/mL, respectively. These values were reached on Day 15 of treatment.

Volume of distribution
Not Available
Protein binding
Not Available
Metabolism

Metabolized primarily by the liver.

Route of elimination

Urinary excretion is the major route of elimination of the drug and its metabolites.

Half life

2 hours [ophthalmic solution]

Clearance
Not Available
Toxicity

Oral LD50 is 50 mg/kg in mice and 100 mg/kg in rats. Common adverse reactions of the topical gel formulation include erythema, flushing, skin burning sensation, and contact dermatitis.

Affected organisms
  • Humans and other mammals
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteractionDrug group
7-NitroindazoleBrimonidine may increase the central nervous system depressant (CNS depressant) activities of 7-Nitroindazole.Experimental
7,8-Dichloro-1,2,3,4-tetrahydroisoquinolineThe risk or severity of adverse effects can be increased when 7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline is combined with Brimonidine.Experimental
AcebutololBrimonidine may increase the antihypertensive activities of Acebutolol.Approved
AcepromazineBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Acepromazine.Approved, Vet Approved
AceprometazineBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Aceprometazine.Approved
AdipiplonBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Adipiplon.Investigational
AgomelatineBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Agomelatine.Approved, Investigational
AlaproclateThe risk or severity of adverse effects can be increased when Brimonidine is combined with Alaproclate.Experimental
AldesleukinThe risk or severity of adverse effects can be increased when Aldesleukin is combined with Brimonidine.Approved
AlfaxaloneBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Alfaxalone.Vet Approved
AlfentanilBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Alfentanil.Approved, Illicit
AlfuzosinAlfuzosin may increase the hypotensive activities of Brimonidine.Approved, Investigational
AliskirenBrimonidine may increase the antihypertensive activities of Aliskiren.Approved, Investigational
AllopregnanoloneBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Allopregnanolone.Investigational
AlphacetylmethadolBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Alphacetylmethadol.Experimental, Illicit
AlphaprodineBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Alphaprodine.Illicit
AlprazolamBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Alprazolam.Approved, Illicit, Investigational
AlprenololBrimonidine may increase the antihypertensive activities of Alprenolol.Approved, Withdrawn
AmbrisentanBrimonidine may increase the antihypertensive activities of Ambrisentan.Approved, Investigational
AmifostineBrimonidine may increase the hypotensive activities of Amifostine.Approved, Investigational
AmilorideThe risk or severity of adverse effects can be increased when Brimonidine is combined with Amiloride.Approved
AmineptineAmineptine may decrease the antihypertensive activities of Brimonidine.Illicit, Withdrawn
AmiodaroneThe risk or severity of adverse effects can be increased when Amiodarone is combined with Brimonidine.Approved, Investigational
AmisulprideBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Amisulpride.Approved, Investigational
AmitriptylineBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Amitriptyline.Approved
AmlodipineBrimonidine may increase the antihypertensive activities of Amlodipine.Approved
AmobarbitalBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Amobarbital.Approved, Illicit
AmoxapineBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Amoxapine.Approved
AmperozideBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Amperozide.Experimental
AmphetamineThe risk or severity of adverse effects can be increased when Amphetamine is combined with Brimonidine.Approved, Illicit
Amphotericin BThe risk or severity of adverse effects can be increased when Amphotericin B is combined with Brimonidine.Approved, Investigational
Amyl NitriteThe risk or severity of adverse effects can be increased when Brimonidine is combined with Amyl Nitrite.Approved
ApomorphineThe risk or severity of adverse effects can be increased when Apomorphine is combined with Brimonidine.Approved, Investigational
ApraclonidineThe risk or severity of adverse effects can be increased when Brimonidine is combined with Apraclonidine.Approved
AripiprazoleAripiprazole may increase the hypotensive activities of Brimonidine.Approved, Investigational
ArotinololBrimonidine may increase the atrioventricular blocking (AV block) activities of Arotinolol.Approved, Investigational
Arsenic trioxideThe risk or severity of adverse effects can be increased when Arsenic trioxide is combined with Brimonidine.Approved, Investigational
ArticaineBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Articaine.Approved
AsenapineBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Asenapine.Approved
AtenololBrimonidine may increase the antihypertensive activities of Atenolol.Approved
AvanafilAvanafil may increase the antihypertensive activities of Brimonidine.Approved
AzaperoneBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Azaperone.Investigational, Vet Approved
AzelastineBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Azelastine.Approved
Azilsartan medoxomilThe risk or severity of adverse effects can be increased when Brimonidine is combined with Azilsartan medoxomil.Approved
BaclofenBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Baclofen.Approved
BarbexacloneBarbexaclone may increase the hypotensive activities of Brimonidine.Experimental
BarbitalBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Barbital.Illicit
BarnidipineThe risk or severity of adverse effects can be increased when Barnidipine is combined with Brimonidine.Approved
BefunololBrimonidine may increase the atrioventricular blocking (AV block) activities of Befunolol.Experimental
BenazeprilBrimonidine may increase the antihypertensive activities of Benazepril.Approved, Investigational
BendroflumethiazideBrimonidine may increase the antihypertensive activities of Bendroflumethiazide.Approved
BenmoxinThe risk or severity of adverse effects can be increased when Benmoxin is combined with Brimonidine.Withdrawn
BenperidolBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Benperidol.Investigational
BenzocaineBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Benzocaine.Approved
Benzyl alcoholBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Benzyl alcohol.Approved
Benzylpenicilloyl PolylysineBrimonidine may decrease effectiveness of Benzylpenicilloyl Polylysine as a diagnostic agent.Approved
BepridilBrimonidine may increase the antihypertensive activities of Bepridil.Approved, Withdrawn
BetaxololBrimonidine may increase the antihypertensive activities of Betaxolol.Approved
BethanidineBrimonidine may increase the antihypertensive activities of Bethanidine.Approved
BevantololBrimonidine may increase the atrioventricular blocking (AV block) activities of Bevantolol.Approved
BietaserpineBrimonidine may increase the antihypertensive activities of Bietaserpine.Experimental
BimatoprostBrimonidine may increase the antihypertensive activities of Bimatoprost.Approved, Investigational
BisoprololBrimonidine may increase the antihypertensive activities of Bisoprolol.Approved
BopindololBrimonidine may increase the atrioventricular blocking (AV block) activities of Bopindolol.Approved
BortezomibThe risk or severity of adverse effects can be increased when Bortezomib is combined with Brimonidine.Approved, Investigational
BosentanBrimonidine may increase the antihypertensive activities of Bosentan.Approved, Investigational
BQ-123Brimonidine may increase the antihypertensive activities of BQ-123.Investigational
BretyliumBrimonidine may increase the antihypertensive activities of Bretylium.Approved
BrexpiprazoleBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Brexpiprazole.Approved
BrofaromineThe risk or severity of adverse effects can be increased when Brofaromine is combined with Brimonidine.Experimental
BromazepamBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Bromazepam.Approved, Illicit
BromisovalBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Bromisoval.Experimental
BromocriptineThe risk or severity of adverse effects can be increased when Bromocriptine is combined with Brimonidine.Approved, Investigational
BromperidolBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Bromperidol.Investigational
BrompheniramineBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Brompheniramine.Approved
BrotizolamBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Brotizolam.Approved, Investigational, Withdrawn
BucindololBrimonidine may increase the atrioventricular blocking (AV block) activities of Bucindolol.Investigational
BufuralolBrimonidine may increase the atrioventricular blocking (AV block) activities of Bufuralol.Experimental, Investigational
BumetanideThe risk or severity of adverse effects can be increased when Brimonidine is combined with Bumetanide.Approved
BunazosinBunazosin may decrease the vasoconstricting activities of Brimonidine.Investigational
BupivacaineBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Bupivacaine.Approved, Investigational
BupranololBrimonidine may increase the antihypertensive activities of Bupranolol.Approved
BuprenorphineBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.Approved, Illicit, Investigational, Vet Approved
BuspironeBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Buspirone.Approved, Investigational
ButabarbitalBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Butabarbital.Approved, Illicit
ButacaineBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Butacaine.Vet Approved
ButalbitalBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Butalbital.Approved, Illicit
ButambenBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Butamben.Approved
ButethalBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Butethal.Approved, Illicit
ButorphanolBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Butorphanol.Approved, Illicit, Vet Approved
CabergolineCabergoline may increase the hypertensive activities of Brimonidine.Approved
CadralazineBrimonidine may increase the antihypertensive activities of Cadralazine.Experimental
CafedrineBrimonidine may increase the antihypertensive activities of Cafedrine.Investigational
CanagliflozinThe risk or severity of adverse effects can be increased when Brimonidine is combined with Canagliflozin.Approved
CandesartanBrimonidine may increase the antihypertensive activities of Candesartan.Experimental
Candesartan cilexetilBrimonidine may increase the antihypertensive activities of Candesartan cilexetil.Approved
CandoxatrilBrimonidine may increase the antihypertensive activities of Candoxatril.Experimental
CanertinibBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Canertinib.Investigational
CaptoprilBrimonidine may increase the antihypertensive activities of Captopril.Approved
CarbamazepineBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Carbamazepine.Approved, Investigational
CarbetocinThe risk or severity of adverse effects can be increased when Carbetocin is combined with Brimonidine.Approved
CarbinoxamineBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Carbinoxamine.Approved
CarfentanilBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Carfentanil.Illicit, Investigational, Vet Approved
CarisoprodolBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Carisoprodol.Approved
CaroxazoneThe risk or severity of adverse effects can be increased when Caroxazone is combined with Brimonidine.Withdrawn
CarteololBrimonidine may increase the antihypertensive activities of Carteolol.Approved
CarvedilolBrimonidine may increase the antihypertensive activities of Carvedilol.Approved, Investigational
CeliprololBrimonidine may increase the antihypertensive activities of Celiprolol.Approved, Investigational
CetirizineBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Cetirizine.Approved
Chloral hydrateBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Chloral hydrate.Approved, Illicit, Vet Approved
ChlordiazepoxideBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Chlordiazepoxide.Approved, Illicit
ChlormezanoneBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Chlormezanone.Approved, Investigational, Withdrawn
ChloroprocaineBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Chloroprocaine.Approved
ChlorothiazideBrimonidine may increase the antihypertensive activities of Chlorothiazide.Approved, Vet Approved
ChlorphenamineBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Chlorphenamine.Approved
ChlorpromazineBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Chlorpromazine.Approved, Vet Approved
ChlorprothixeneBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Chlorprothixene.Approved, Investigational, Withdrawn
ChlorthalidoneBrimonidine may increase the antihypertensive activities of Chlorthalidone.Approved
ChlorzoxazoneBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Chlorzoxazone.Approved
CicletanineBrimonidine may increase the antihypertensive activities of Cicletanine.Investigational
CilazaprilBrimonidine may increase the antihypertensive activities of Cilazapril.Approved
CilnidipineThe risk or severity of adverse effects can be increased when Cilnidipine is combined with Brimonidine.Approved, Investigational
CinchocaineBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Cinchocaine.Approved, Vet Approved
CitalopramThe risk or severity of adverse effects can be increased when Brimonidine is combined with Citalopram.Approved
ClemastineBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Clemastine.Approved
ClevidipineThe risk or severity of adverse effects can be increased when Brimonidine is combined with Clevidipine.Approved
ClidiniumBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Clidinium.Approved
ClobazamBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Clobazam.Approved, Illicit
ClofarabineThe risk or severity of adverse effects can be increased when Clofarabine is combined with Brimonidine.Approved, Investigational
clomethiazoleBrimonidine may increase the central nervous system depressant (CNS depressant) activities of clomethiazole.Investigational
ClomipramineBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Clomipramine.Approved, Vet Approved
ClonazepamBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Clonazepam.Approved, Illicit
ClonidineBrimonidine may increase the antihypertensive activities of Clonidine.Approved
ClopenthixolBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Clopenthixol.Experimental
CloranololBrimonidine may increase the antihypertensive activities of Cloranolol.Experimental
ClorazepateBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Clorazepate.Approved, Illicit
ClothiapineBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Clothiapine.Experimental
ClozapineBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Clozapine.Approved
CocaineBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Cocaine.Approved, Illicit
CodeineBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Codeine.Approved, Illicit
ConivaptanThe risk or severity of adverse effects can be increased when Conivaptan is combined with Brimonidine.Approved, Investigational
CryptenamineBrimonidine may increase the antihypertensive activities of Cryptenamine.Approved
CyclizineBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Cyclizine.Approved
CyclobenzaprineBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Cyclobenzaprine.Approved
CyclopenthiazideBrimonidine may increase the antihypertensive activities of Cyclopenthiazide.Experimental
CyclothiazideBrimonidine may increase the antihypertensive activities of Cyclothiazide.Approved
CyproheptadineBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Cyproheptadine.Approved
DantroleneBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Dantrolene.Approved
DapagliflozinThe risk or severity of adverse effects can be increased when Brimonidine is combined with Dapagliflozin.Approved
DapiprazoleBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Dapiprazole.Approved
DapoxetineThe risk or severity of adverse effects can be increased when Brimonidine is combined with Dapoxetine.Investigational
DebrisoquinBrimonidine may increase the antihypertensive activities of Debrisoquin.Approved, Investigational
DelaprilBrimonidine may increase the antihypertensive activities of Delapril.Experimental
DeramciclaneBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Deramciclane.Investigational
DeserpidineBrimonidine may increase the antihypertensive activities of Deserpidine.Approved
DesfluraneBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Desflurane.Approved
DesipramineBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Desipramine.Approved
DesloratadineBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Desloratadine.Approved, Investigational
DesvenlafaxineDesvenlafaxine may increase the tachycardic activities of Brimonidine.Approved
DetomidineBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Detomidine.Vet Approved
DexbrompheniramineBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Dexbrompheniramine.Approved
DexmedetomidineBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Dexmedetomidine.Approved, Vet Approved
DextromoramideBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Dextromoramide.Experimental, Illicit
DextropropoxypheneBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Dextropropoxyphene.Approved, Illicit, Investigational, Withdrawn
DezocineBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Dezocine.Approved, Investigational
DiazepamBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Diazepam.Approved, Illicit, Vet Approved
DiazoxideDiazoxide may increase the hypotensive activities of Brimonidine.Approved
DibenzepinDibenzepin may decrease the antihypertensive activities of Brimonidine.Experimental
DiclofenamideThe risk or severity of adverse effects can be increased when Brimonidine is combined with Diclofenamide.Approved
Diethyl etherBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Diethyl ether.Experimental
diethylnorspermineBrimonidine may increase the antihypertensive activities of diethylnorspermine.Investigational
DifenoxinBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Difenoxin.Approved, Illicit
DigoxinBrimonidine may increase the bradycardic activities of Digoxin.Approved
DihydralazineBrimonidine may increase the antihypertensive activities of Dihydralazine.Investigational
DihydrocodeineBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Dihydrocodeine.Approved, Illicit
DihydroergotamineDihydroergotamine may increase the hypertensive activities of Brimonidine.Approved
DihydroetorphineBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Dihydroetorphine.Experimental, Illicit
DihydromorphineBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Dihydromorphine.Experimental, Illicit
DiltiazemBrimonidine may increase the antihypertensive activities of Diltiazem.Approved
DimenhydrinateBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Dimenhydrinate.Approved
DinutuximabThe risk or severity of adverse effects can be increased when Brimonidine is combined with Dinutuximab.Approved
DiphenhydramineBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Diphenhydramine.Approved
DiphenoxylateBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Diphenoxylate.Approved, Illicit
DipyridamoleThe risk or severity of adverse effects can be increased when Brimonidine is combined with Dipyridamole.Approved
DixyrazineBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Dixyrazine.Experimental
DoramectinBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Doramectin.Vet Approved
DorzolamideBrimonidine may increase the antihypertensive activities of Dorzolamide.Approved
DosulepinDosulepin may decrease the antihypertensive activities of Brimonidine.Approved
DoxazosinBrimonidine may increase the antihypertensive activities of Doxazosin.Approved
DoxepinBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Doxepin.Approved
DoxylamineDoxylamine may increase the central nervous system depressant (CNS depressant) activities of Brimonidine.Approved, Vet Approved
DPDPEBrimonidine may increase the central nervous system depressant (CNS depressant) activities of DPDPE.Experimental
DronabinolDronabinol may increase the central nervous system depressant (CNS depressant) activities of Brimonidine.Approved, Illicit
DroperidolDroperidol may increase the central nervous system depressant (CNS depressant) activities of Brimonidine.Approved, Vet Approved
DrotebanolBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Drotebanol.Experimental, Illicit
DuloxetineBrimonidine may increase the orthostatic hypotensive activities of Duloxetine.Approved
DyclonineBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Dyclonine.Approved
EcgonineBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Ecgonine.Experimental, Illicit
EcopipamBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Ecopipam.Investigational
EfavirenzBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Efavirenz.Approved, Investigational
EfonidipineBrimonidine may increase the antihypertensive activities of Efonidipine.Approved, Investigational
EltanoloneBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Eltanolone.Investigational
EmpagliflozinThe risk or severity of adverse effects can be increased when Brimonidine is combined with Empagliflozin.Approved
EnalaprilBrimonidine may increase the antihypertensive activities of Enalapril.Approved, Vet Approved
EnalaprilatBrimonidine may increase the antihypertensive activities of Enalaprilat.Approved
EndralazineBrimonidine may increase the antihypertensive activities of Endralazine.Experimental
EnfluraneBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Enflurane.Approved, Investigational, Vet Approved
EntacaponeBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Entacapone.Approved, Investigational
EpanololBrimonidine may increase the antihypertensive activities of Epanolol.Experimental
EplerenoneThe risk or severity of adverse effects can be increased when Brimonidine is combined with Eplerenone.Approved
EpoprostenolBrimonidine may increase the antihypertensive activities of Epoprostenol.Approved
EprosartanBrimonidine may increase the antihypertensive activities of Eprosartan.Approved
Ergoloid mesylateErgoloid mesylate may increase the hypertensive activities of Brimonidine.Approved
ErgonovineErgonovine may increase the hypertensive activities of Brimonidine.Approved
ErgotamineErgotamine may increase the hypertensive activities of Brimonidine.Approved
EscitalopramThe risk or severity of adverse effects can be increased when Brimonidine is combined with Escitalopram.Approved, Investigational
EsmirtazapineEsmirtazapine may decrease the antihypertensive activities of Brimonidine.Investigational
EsmololBrimonidine may increase the atrioventricular blocking (AV block) activities of Esmolol.Approved
EstazolamBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Estazolam.Approved, Illicit
EszopicloneBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Eszopiclone.Approved
Etacrynic acidThe risk or severity of adverse effects can be increased when Brimonidine is combined with Etacrynic acid.Approved
EthanolBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Ethanol.Approved
EthchlorvynolBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Ethchlorvynol.Approved, Illicit, Withdrawn
EthosuximideBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Ethosuximide.Approved
EthotoinBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Ethotoin.Approved
Ethyl carbamateBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Ethyl carbamate.Withdrawn
Ethyl chlorideBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Ethyl chloride.Experimental, Investigational
Ethyl loflazepateBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Ethyl loflazepate.Approved, Illicit
EthylmorphineBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Ethylmorphine.Approved, Illicit
EtidocaineBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Etidocaine.Approved
EtifoxineBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Etifoxine.Investigational, Withdrawn
EtizolamBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Etizolam.Approved
EtomidateBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Etomidate.Approved
EtoperidoneThe risk or severity of adverse effects can be increased when Brimonidine is combined with Etoperidone.Withdrawn
EtorphineBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Etorphine.Illicit, Vet Approved
EzogabineBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Ezogabine.Approved
FelbamateBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Felbamate.Approved
FelodipineBrimonidine may increase the antihypertensive activities of Felodipine.Approved, Investigational
FencamfamineBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Fencamfamine.Approved, Illicit, Withdrawn
FenoldopamBrimonidine may increase the antihypertensive activities of Fenoldopam.Approved
FentanylBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Fentanyl.Approved, Illicit, Investigational, Vet Approved
Ferulic acidBrimonidine may increase the antihypertensive activities of Ferulic acid.Experimental
FexofenadineBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Fexofenadine.Approved
FimasartanThe risk or severity of adverse effects can be increased when Fimasartan is combined with Brimonidine.Approved, Investigational
FlibanserinBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Flibanserin.Approved
FluanisoneBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Fluanisone.Experimental
FludiazepamBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Fludiazepam.Approved, Illicit
FlunarizineBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Flunarizine.Approved
FlunitrazepamBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Flunitrazepam.Approved, Illicit
FluoxetineThe risk or severity of adverse effects can be increased when Brimonidine is combined with Fluoxetine.Approved, Vet Approved
FlupentixolBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Flupentixol.Approved, Withdrawn
FluphenazineBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Fluphenazine.Approved
FlurazepamBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Flurazepam.Approved, Illicit
FluspirileneBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Fluspirilene.Approved, Investigational
Fluticasone propionateBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Fluticasone propionate.Approved
FluvoxamineBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Fluvoxamine.Approved, Investigational
FosinoprilBrimonidine may increase the antihypertensive activities of Fosinopril.Approved
FosphenytoinBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Fosphenytoin.Approved
FospropofolBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Fospropofol.Approved, Illicit, Investigational
FurazolidoneThe risk or severity of adverse effects can be increased when Furazolidone is combined with Brimonidine.Approved, Investigational, Vet Approved
FurosemideThe risk or severity of adverse effects can be increased when Brimonidine is combined with Furosemide.Approved, Vet Approved
GabapentinBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Gabapentin.Approved, Investigational
Gabapentin EnacarbilBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Gabapentin Enacarbil.Approved
Gamma Hydroxybutyric AcidBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Gamma Hydroxybutyric Acid.Approved, Illicit, Investigational
GepironeBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Gepirone.Investigational
GlutethimideBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Glutethimide.Approved, Illicit
GuanabenzBrimonidine may increase the antihypertensive activities of Guanabenz.Approved, Investigational
GuanadrelBrimonidine may increase the antihypertensive activities of Guanadrel.Approved
GuanazodineBrimonidine may increase the antihypertensive activities of Guanazodine.Experimental
GuanethidineBrimonidine may increase the antihypertensive activities of Guanethidine.Approved
GuanfacineBrimonidine may increase the antihypertensive activities of Guanfacine.Approved, Investigational
GuanoclorBrimonidine may increase the antihypertensive activities of Guanoclor.Experimental
GuanoxabenzBrimonidine may increase the antihypertensive activities of Guanoxabenz.Experimental
GuanoxanBrimonidine may increase the antihypertensive activities of Guanoxan.Experimental
HalazepamBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Halazepam.Approved, Illicit, Withdrawn
HaloperidolBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Haloperidol.Approved
HalothaneBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Halothane.Approved, Vet Approved
HarmalineThe risk or severity of adverse effects can be increased when Harmaline is combined with Brimonidine.Experimental
HeroinBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Heroin.Approved, Illicit, Investigational
HexamethoniumBrimonidine may increase the antihypertensive activities of Hexamethonium.Experimental
HexobarbitalBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Hexobarbital.Approved
HyaluronidaseHyaluronidase may increase the vasoconstricting activities of Brimonidine.Approved, Investigational
HydracarbazineThe risk or severity of adverse effects can be increased when Hydracarbazine is combined with Brimonidine.Experimental
HydralazineBrimonidine may increase the antihypertensive activities of Hydralazine.Approved
HydrochlorothiazideBrimonidine may increase the antihypertensive activities of Hydrochlorothiazide.Approved, Vet Approved
HydrocodoneBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved, Illicit
HydroflumethiazideBrimonidine may increase the antihypertensive activities of Hydroflumethiazide.Approved, Investigational
HydromorphoneBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Hydromorphone.Approved, Illicit
HydroxyzineHydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Brimonidine.Approved
IloperidoneBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Iloperidone.Approved
IloprostIloprost may increase the hypotensive activities of Brimonidine.Approved, Investigational
ImidaprilBrimonidine may increase the antihypertensive activities of Imidapril.Investigational
ImipramineBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Imipramine.Approved
IndalpineThe risk or severity of adverse effects can be increased when Brimonidine is combined with Indalpine.Investigational, Withdrawn
IndapamideBrimonidine may increase the antihypertensive activities of Indapamide.Approved
IndenololBrimonidine may increase the antihypertensive activities of Indenolol.Withdrawn
IndiplonBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Indiplon.Investigational
IndoraminBrimonidine may increase the antihypertensive activities of Indoramin.Withdrawn
IobenguaneThe therapeutic efficacy of Iobenguane can be decreased when used in combination with Brimonidine.Approved, Investigational
IprindoleIprindole may decrease the antihypertensive activities of Brimonidine.Experimental
IproclozideThe risk or severity of adverse effects can be increased when Iproclozide is combined with Brimonidine.Withdrawn
IproniazidThe risk or severity of adverse effects can be increased when Iproniazid is combined with Brimonidine.Withdrawn
IrbesartanBrimonidine may increase the antihypertensive activities of Irbesartan.Approved, Investigational
IsocarboxazidThe risk or severity of adverse effects can be increased when Isocarboxazid is combined with Brimonidine.Approved
IsofluraneBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Isoflurane.Approved, Vet Approved
Isosorbide DinitrateThe risk or severity of adverse effects can be increased when Brimonidine is combined with Isosorbide Dinitrate.Approved
Isosorbide MononitrateThe risk or severity of adverse effects can be increased when Brimonidine is combined with Isosorbide Mononitrate.Approved
IsoxsuprineThe risk or severity of adverse effects can be increased when Brimonidine is combined with Isoxsuprine.Approved, Withdrawn
IsradipineBrimonidine may increase the antihypertensive activities of Isradipine.Approved
KetamineBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Ketamine.Approved, Vet Approved
KetanserinBrimonidine may increase the antihypertensive activities of Ketanserin.Investigational
KetazolamBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Ketazolam.Approved
KetobemidoneBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Ketobemidone.Approved, Investigational
LabetalolBrimonidine may increase the antihypertensive activities of Labetalol.Approved
LacidipineBrimonidine may increase the antihypertensive activities of Lacidipine.Approved, Investigational
LamotrigineBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Lamotrigine.Approved, Investigational
LandiololBrimonidine may increase the atrioventricular blocking (AV block) activities of Landiolol.Investigational
LatanoprostBrimonidine may increase the antihypertensive activities of Latanoprost.Approved, Investigational
LercanidipineBrimonidine may increase the antihypertensive activities of Lercanidipine.Approved, Investigational
LevetiracetamBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Levetiracetam.Approved, Investigational
LevobunololThe risk or severity of adverse effects can be increased when Brimonidine is combined with Levobunolol.Approved
LevobupivacaineBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Levobupivacaine.Approved, Investigational
LevocabastineBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Levocabastine.Approved
LevocetirizineBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Levocetirizine.Approved
LevodopaBrimonidine may increase the orthostatic hypotensive activities of Levodopa.Approved
Levomethadyl AcetateBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Levomethadyl Acetate.Approved, Investigational
LevomilnacipranLevomilnacipran may increase the tachycardic activities of Brimonidine.Approved
LevorphanolBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Levorphanol.Approved
LevosimendanThe risk or severity of adverse effects can be increased when Levosimendan is combined with Brimonidine.Approved, Investigational
LidocaineBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Lidocaine.Approved, Vet Approved
LinsidomineBrimonidine may increase the antihypertensive activities of Linsidomine.Experimental
LisinoprilBrimonidine may increase the antihypertensive activities of Lisinopril.Approved, Investigational
LithiumBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Lithium.Approved
LofentanilBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Lofentanil.Illicit
LofepramineLofepramine may decrease the antihypertensive activities of Brimonidine.Experimental
LofexidineBrimonidine may increase the antihypertensive activities of Lofexidine.Approved, Investigational
LoprazolamBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Loprazolam.Experimental
LoratadineBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Loratadine.Approved
LorazepamBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Lorazepam.Approved
LormetazepamBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Lormetazepam.Approved
LosartanBrimonidine may increase the antihypertensive activities of Losartan.Approved
LoxapineBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Loxapine.Approved
LurasidoneBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Lurasidone.Approved
MacitentanBrimonidine may increase the antihypertensive activities of Macitentan.Approved
Magnesium SulfateMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Brimonidine.Approved, Vet Approved
ManidipineBrimonidine may increase the antihypertensive activities of Manidipine.Approved, Investigational
MannitolThe risk or severity of adverse effects can be increased when Brimonidine is combined with Mannitol.Approved, Investigational
MaprotilineBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Maprotiline.Approved
MebanazineThe risk or severity of adverse effects can be increased when Mebanazine is combined with Brimonidine.Withdrawn
MebicarBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Mebicar.Experimental
MecamylamineBrimonidine may increase the antihypertensive activities of Mecamylamine.Approved
MeclizineBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Meclizine.Approved
MedazepamBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Medazepam.Experimental
MedetomidineBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Medetomidine.Vet Approved
MelatoninBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Melatonin.Approved, Nutraceutical, Vet Approved
MelperoneBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Melperone.Approved, Investigational
MepindololBrimonidine may increase the atrioventricular blocking (AV block) activities of Mepindolol.Experimental
MepivacaineBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Mepivacaine.Approved, Vet Approved
MeprobamateBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Meprobamate.Approved, Illicit
MeptazinolBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Meptazinol.Experimental
MesoridazineBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Mesoridazine.Approved, Investigational
MetaxaloneBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Metaxalone.Approved
MethadoneBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Methadone.Approved
Methadyl AcetateBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Methadyl Acetate.Approved, Illicit
MethapyrileneBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Methapyrilene.Withdrawn
MethaqualoneBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Methaqualone.Illicit, Withdrawn
MethazolamideThe risk or severity of adverse effects can be increased when Brimonidine is combined with Methazolamide.Approved
MethocarbamolBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Methocarbamol.Approved, Vet Approved
MethohexitalBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Methohexital.Approved
MethoserpidineBrimonidine may increase the antihypertensive activities of Methoserpidine.Experimental
MethotrimeprazineBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.Approved
MethoxyfluraneBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Methoxyflurane.Approved, Investigational, Vet Approved
MethsuximideBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Methsuximide.Approved
MethyclothiazideThe risk or severity of adverse effects can be increased when Methyclothiazide is combined with Brimonidine.Approved
MethyldopaBrimonidine may increase the antihypertensive activities of Methyldopa.Approved
MethylecgonineBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Methylecgonine.Experimental
Methylene blueThe risk or severity of adverse effects can be increased when Methylene blue is combined with Brimonidine.Approved, Investigational
MethylergometrineMethylergometrine may increase the hypertensive activities of Brimonidine.Approved
MethylphenidateMethylphenidate may decrease the antihypertensive activities of Brimonidine.Approved, Investigational
MethylphenobarbitalBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Methylphenobarbital.Approved
MetipranololBrimonidine may increase the antihypertensive activities of Metipranolol.Approved
MetolazoneBrimonidine may increase the antihypertensive activities of Metolazone.Approved
MetoprololBrimonidine may increase the antihypertensive activities of Metoprolol.Approved, Investigational
MetyrosineBrimonidine may increase the sedative activities of Metyrosine.Approved
MianserinThe therapeutic efficacy of Brimonidine can be decreased when used in combination with Mianserin.Approved, Investigational
MibefradilBrimonidine may increase the antihypertensive activities of Mibefradil.Investigational, Withdrawn
MidazolamBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Midazolam.Approved, Illicit
MilnacipranMilnacipran may increase the tachycardic activities of Brimonidine.Approved
MinaprineThe risk or severity of adverse effects can be increased when Minaprine is combined with Brimonidine.Approved
MinocyclineMinocycline may increase the central nervous system depressant (CNS depressant) activities of Brimonidine.Approved, Investigational
MinoxidilBrimonidine may increase the antihypertensive activities of Minoxidil.Approved
MirodenafilMirodenafil may increase the antihypertensive activities of Brimonidine.Investigational
MirtazapineMirtazapine may decrease the antihypertensive activities of Brimonidine.Approved
MoclobemideThe risk or severity of adverse effects can be increased when Moclobemide is combined with Brimonidine.Approved
MoexiprilBrimonidine may increase the antihypertensive activities of Moexipril.Approved
MolindoneBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Molindone.Approved
MolsidomineMolsidomine may increase the hypotensive activities of Brimonidine.Approved, Investigational
MorphineBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Morphine.Approved, Investigational
MoxonidineBrimonidine may increase the antihypertensive activities of Moxonidine.Approved, Investigational
MuzolimineBrimonidine may increase the antihypertensive activities of Muzolimine.Experimental
NabiloneNabilone may increase the central nervous system depressant (CNS depressant) activities of Brimonidine.Approved, Investigational
NadololBrimonidine may increase the antihypertensive activities of Nadolol.Approved
NaftopidilBrimonidine may increase the antihypertensive activities of Naftopidil.Investigational
NalbuphineBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Nalbuphine.Approved
NebivololBrimonidine may increase the antihypertensive activities of Nebivolol.Approved, Investigational
NefazodoneThe risk or severity of adverse effects can be increased when Brimonidine is combined with Nefazodone.Approved, Withdrawn
NesiritideThe risk or severity of adverse effects can be increased when Brimonidine is combined with Nesiritide.Approved, Investigational
NialamideThe risk or severity of adverse effects can be increased when Nialamide is combined with Brimonidine.Withdrawn
NicardipineBrimonidine may increase the antihypertensive activities of Nicardipine.Approved
NicorandilNicorandil may increase the hypotensive activities of Brimonidine.Approved, Investigational
NifedipineThe risk or severity of adverse effects can be increased when Brimonidine is combined with Nifedipine.Approved
NiguldipineBrimonidine may increase the antihypertensive activities of Niguldipine.Experimental
NilvadipineBrimonidine may increase the antihypertensive activities of Nilvadipine.Approved, Investigational
NimodipineBrimonidine may increase the antihypertensive activities of Nimodipine.Approved
NisoldipineBrimonidine may increase the antihypertensive activities of Nisoldipine.Approved
NitrazepamBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Nitrazepam.Approved
NitrendipineBrimonidine may increase the antihypertensive activities of Nitrendipine.Approved, Investigational
Nitric OxideThe risk or severity of adverse effects can be increased when Nitric Oxide is combined with Brimonidine.Approved
NitroglycerinThe risk or severity of adverse effects can be increased when Brimonidine is combined with Nitroglycerin.Approved, Investigational
NitroprussideBrimonidine may increase the antihypertensive activities of Nitroprusside.Approved
Nitrous oxideBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Nitrous oxide.Approved, Vet Approved
NorfluraneBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Norflurane.Investigational
NormethadoneBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Normethadone.Approved, Illicit
NortriptylineBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Nortriptyline.Approved
ObinutuzumabBrimonidine may increase the hypotensive activities of Obinutuzumab.Approved
OctamoxinThe risk or severity of adverse effects can be increased when Octamoxin is combined with Brimonidine.Withdrawn
OlanzapineBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Olanzapine.Approved, Investigational
OlmesartanBrimonidine may increase the antihypertensive activities of Olmesartan.Approved, Investigational
OlopatadineBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Olopatadine.Approved
OmapatrilatBrimonidine may increase the antihypertensive activities of Omapatrilat.Investigational
OndansetronBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Ondansetron.Approved
OpipramolOpipramol may decrease the antihypertensive activities of Brimonidine.Investigational
OpiumBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Opium.Approved, Illicit
OrphenadrineBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.Approved
OsanetantBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Osanetant.Investigational
OxazepamBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Oxazepam.Approved
OxethazaineBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Oxethazaine.Approved, Investigational
OxprenololBrimonidine may increase the antihypertensive activities of Oxprenolol.Approved
OxybuprocaineBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Oxybuprocaine.Approved
OxycodoneBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Oxycodone.Approved, Illicit, Investigational
OxymorphoneBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Oxymorphone.Approved, Investigational, Vet Approved
PaclitaxelThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Brimonidine.Approved, Vet Approved
PaliperidoneBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Paliperidone.Approved
PapaverineThe risk or severity of adverse effects can be increased when Brimonidine is combined with Papaverine.Approved
ParaldehydeBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Paraldehyde.Approved, Investigational
PargylineThe risk or severity of adverse effects can be increased when Pargyline is combined with Brimonidine.Approved
ParoxetineThe risk or severity of adverse effects can be increased when Brimonidine is combined with Paroxetine.Approved, Investigational
PenbutololBrimonidine may increase the antihypertensive activities of Penbutolol.Approved, Investigational
PenfluridolBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Penfluridol.Experimental
PentazocineBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Pentazocine.Approved, Vet Approved
PentobarbitalBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Pentobarbital.Approved, Vet Approved
PentoliniumBrimonidine may increase the antihypertensive activities of Pentolinium.Approved
PentoxifyllinePentoxifylline may increase the hypotensive activities of Brimonidine.Approved, Investigational
PerampanelPerampanel may increase the central nervous system depressant (CNS depressant) activities of Brimonidine.Approved
PerazineBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Perazine.Investigational
PerindoprilBrimonidine may increase the antihypertensive activities of Perindopril.Approved
PerospironeBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Perospirone.Approved
PerphenazineBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Perphenazine.Approved
PethidineBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Pethidine.Approved
PhenazocineBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Phenazocine.Experimental
PhenelzineThe risk or severity of adverse effects can be increased when Phenelzine is combined with Brimonidine.Approved
PhenibutBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Phenibut.Experimental
PheniprazineThe risk or severity of adverse effects can be increased when Pheniprazine is combined with Brimonidine.Withdrawn
PhenobarbitalBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Phenobarbital.Approved
PhenoperidineBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Phenoperidine.Experimental
PhenoxybenzamineBrimonidine may increase the antihypertensive activities of Phenoxybenzamine.Approved
PhenoxyethanolBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Phenoxyethanol.Approved
PhenoxypropazineThe risk or severity of adverse effects can be increased when Phenoxypropazine is combined with Brimonidine.Withdrawn
PhentolamineBrimonidine may increase the antihypertensive activities of Phentolamine.Approved
PhenytoinBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Phenytoin.Approved, Vet Approved
PimozideBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Pimozide.Approved
PinacidilBrimonidine may increase the antihypertensive activities of Pinacidil.Withdrawn
PindololBrimonidine may increase the antihypertensive activities of Pindolol.Approved
PipamperoneBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Pipamperone.Approved, Investigational
PipotiazineBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Pipotiazine.Approved, Investigational
PiritramideBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Piritramide.Investigational
PirlindoleThe risk or severity of adverse effects can be increased when Pirlindole is combined with Brimonidine.Approved
PivhydrazineThe risk or severity of adverse effects can be increased when Pivhydrazine is combined with Brimonidine.Withdrawn
PizotifenBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Pizotifen.Approved
Platelet Activating FactorBrimonidine may increase the antihypertensive activities of Platelet Activating Factor.Experimental
PolythiazideBrimonidine may increase the antihypertensive activities of Polythiazide.Approved
PomalidomideBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Pomalidomide.Approved
PractololBrimonidine may increase the atrioventricular blocking (AV block) activities of Practolol.Approved
PramipexoleBrimonidine may increase the sedative activities of Pramipexole.Approved, Investigational
PramocaineBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Pramocaine.Approved
PrazepamBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Prazepam.Approved, Illicit
PrazosinBrimonidine may increase the antihypertensive activities of Prazosin.Approved
PregabalinBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Pregabalin.Approved, Illicit, Investigational
PrilocaineBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Prilocaine.Approved
PrimidoneBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Primidone.Approved, Vet Approved
ProcaineBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Procaine.Approved, Investigational, Vet Approved
ProcarbazineThe risk or severity of adverse effects can be increased when Procarbazine is combined with Brimonidine.Approved
ProchlorperazineBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Prochlorperazine.Approved, Vet Approved
PromazineBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Promazine.Approved, Vet Approved
PromethazineBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Promethazine.Approved
PropanididBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Propanidid.Experimental
ProparacaineBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Proparacaine.Approved, Vet Approved
PropofolBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Propofol.Approved, Investigational, Vet Approved
PropoxycaineBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Propoxycaine.Approved
PropranololBrimonidine may increase the antihypertensive activities of Propranolol.Approved, Investigational
ProtriptylineBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Protriptyline.Approved
ProxibarbalBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Proxibarbal.Experimental
PSD502Brimonidine may increase the central nervous system depressant (CNS depressant) activities of PSD502.Investigational
QuazepamBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Quazepam.Approved, Illicit
QuetiapineBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Quetiapine.Approved
QuinaprilBrimonidine may increase the antihypertensive activities of Quinapril.Approved, Investigational
QuinineQuinine may increase the hypotensive activities of Brimonidine.Approved
QuinisocaineBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Quinisocaine.Experimental
RacloprideBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Raclopride.Investigational
RamelteonBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Ramelteon.Approved, Investigational
RamiprilBrimonidine may increase the antihypertensive activities of Ramipril.Approved
RasagilineThe risk or severity of adverse effects can be increased when Rasagiline is combined with Brimonidine.Approved
RemifentanilBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Remifentanil.Approved
RemikirenBrimonidine may increase the antihypertensive activities of Remikiren.Approved
RemoxiprideBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Remoxipride.Approved, Withdrawn
RescinnamineBrimonidine may increase the antihypertensive activities of Rescinnamine.Approved
ReserpineBrimonidine may increase the antihypertensive activities of Reserpine.Approved, Investigational
RilmenidineBrimonidine may increase the antihypertensive activities of Rilmenidine.Investigational
RiociguatBrimonidine may increase the antihypertensive activities of Riociguat.Approved
RisperidoneBrimonidine may increase the hypotensive activities of Risperidone.Approved, Investigational
RitanserinBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Ritanserin.Investigational
RituximabBrimonidine may increase the hypotensive activities of Rituximab.Approved
RomifidineBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Romifidine.Vet Approved
RopiniroleBrimonidine may increase the sedative activities of Ropinirole.Approved, Investigational
RopivacaineBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Ropivacaine.Approved
RotigotineBrimonidine may increase the sedative activities of Rotigotine.Approved
RufinamideThe risk or severity of adverse effects can be increased when Rufinamide is combined with Brimonidine.Approved
SacubitrilThe risk or severity of adverse effects can be increased when Sacubitril is combined with Brimonidine.Approved
SafrazineThe risk or severity of adverse effects can be increased when Safrazine is combined with Brimonidine.Withdrawn
SaprisartanBrimonidine may increase the antihypertensive activities of Saprisartan.Experimental
ScopolamineBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Scopolamine.Approved
SecobarbitalBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Secobarbital.Approved, Vet Approved
SelegilineThe risk or severity of adverse effects can be increased when Selegiline is combined with Brimonidine.Approved, Investigational, Vet Approved
SelexipagBrimonidine may increase the antihypertensive activities of Selexipag.Approved
SepranoloneBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Sepranolone.Investigational
SertindoleBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Sertindole.Approved, Investigational, Withdrawn
SertralineThe risk or severity of adverse effects can be increased when Brimonidine is combined with Sertraline.Approved
SevofluraneBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Sevoflurane.Approved, Vet Approved
SildenafilSildenafil may increase the antihypertensive activities of Brimonidine.Approved, Investigational
SilodosinSilodosin may decrease the vasoconstricting activities of Brimonidine.Approved
SitaxentanBrimonidine may increase the antihypertensive activities of Sitaxentan.Approved, Investigational, Withdrawn
Sodium NitriteThe risk or severity of adverse effects can be increased when Sodium Nitrite is combined with Brimonidine.Approved
Sodium oxybateSodium oxybate may increase the central nervous system depressant (CNS depressant) activities of Brimonidine.Approved
SotalolBrimonidine may increase the atrioventricular blocking (AV block) activities of Sotalol.Approved
SpiraprilBrimonidine may increase the antihypertensive activities of Spirapril.Approved
SpironolactoneSpironolactone may decrease the vasoconstricting activities of Brimonidine.Approved
StiripentolBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Stiripentol.Approved
StreptokinaseThe risk or severity of adverse effects can be increased when Streptokinase is combined with Brimonidine.Approved, Investigational
SufentanilBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Sufentanil.Approved, Investigational
SulpirideBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Sulpiride.Approved, Investigational
SultoprideBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Sultopride.Experimental
SuvorexantBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Suvorexant.Approved
TadalafilTadalafil may increase the antihypertensive activities of Brimonidine.Approved, Investigational
TalinololBrimonidine may increase the antihypertensive activities of Talinolol.Investigational
TamsulosinThe risk or severity of adverse effects can be increased when Tamsulosin is combined with Brimonidine.Approved, Investigational
TandospironeBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Tandospirone.Investigational
TapentadolTapentadol may increase the central nervous system depressant (CNS depressant) activities of Brimonidine.Approved
TasimelteonBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Tasimelteon.Approved
TelmisartanBrimonidine may increase the antihypertensive activities of Telmisartan.Approved, Investigational
TemazepamBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Temazepam.Approved
TemocaprilBrimonidine may increase the antihypertensive activities of Temocapril.Experimental, Investigational
TerazosinThe risk or severity of adverse effects can be increased when Brimonidine is combined with Terazosin.Approved
TerlipressinBrimonidine may increase the antihypertensive activities of Terlipressin.Approved, Investigational
TertatololBrimonidine may increase the atrioventricular blocking (AV block) activities of Tertatolol.Experimental
TetrabenazineBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Tetrabenazine.Approved
TetracaineBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Tetracaine.Approved, Vet Approved
TetrahydropalmatineBrimonidine may increase the antihypertensive activities of Tetrahydropalmatine.Investigational
TetrodotoxinBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Tetrodotoxin.Investigational
ThalidomideBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.Approved, Investigational, Withdrawn
TheodrenalineBrimonidine may increase the antihypertensive activities of Theodrenaline.Investigational
ThiamylalBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Thiamylal.Approved, Vet Approved
ThiopentalBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Thiopental.Approved, Vet Approved
ThioridazineBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Thioridazine.Approved, Withdrawn
ThiothixeneBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Thiothixene.Approved
TiagabineBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Tiagabine.Approved
TianeptineTianeptine may decrease the antihypertensive activities of Brimonidine.Approved, Investigational
TiaprideBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Tiapride.Approved, Investigational
TiboloneBrimonidine may increase the antihypertensive activities of Tibolone.Approved, Investigational
TicrynafenBrimonidine may increase the antihypertensive activities of Ticrynafen.Withdrawn
TiletamineBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Tiletamine.Vet Approved
TilidineBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Tilidine.Experimental
TimololBrimonidine may increase the antihypertensive activities of Timolol.Approved
TizanidineBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Tizanidine.Approved
TolazolineBrimonidine may increase the antihypertensive activities of Tolazoline.Approved, Vet Approved
TolcaponeBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Tolcapone.Approved, Withdrawn
TolonidineBrimonidine may increase the antihypertensive activities of Tolonidine.Experimental
ToloxatoneThe risk or severity of adverse effects can be increased when Toloxatone is combined with Brimonidine.Approved
TopiramateBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Topiramate.Approved
TorasemideBrimonidine may increase the antihypertensive activities of Torasemide.Approved
TramadolBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Tramadol.Approved, Investigational
TrandolaprilBrimonidine may increase the antihypertensive activities of Trandolapril.Approved
Trans-2-PhenylcyclopropylamineThe risk or severity of adverse effects can be increased when Trans-2-Phenylcyclopropylamine is combined with Brimonidine.Experimental
TranylcypromineThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Brimonidine.Approved
TravoprostBrimonidine may increase the antihypertensive activities of Travoprost.Approved
TrazodoneBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Trazodone.Approved, Investigational
TreprostinilBrimonidine may increase the antihypertensive activities of Treprostinil.Approved, Investigational
TretinoinThe risk or severity of adverse effects can be increased when Tretinoin is combined with Brimonidine.Approved, Investigational, Nutraceutical
TriamtereneThe risk or severity of adverse effects can be increased when Triamterene is combined with Brimonidine.Approved
TriazolamBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Triazolam.Approved
Tricaine methanesulfonateBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Tricaine methanesulfonate.Vet Approved
TrichlormethiazideBrimonidine may increase the antihypertensive activities of Trichlormethiazide.Approved, Vet Approved
TrichloroethyleneBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Trichloroethylene.Approved
TrifluoperazineBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Trifluoperazine.Approved
TrifluperidolBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Trifluperidol.Experimental
TriflupromazineBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Triflupromazine.Approved, Vet Approved
TrimazosinBrimonidine may increase the antihypertensive activities of Trimazosin.Experimental
TrimethaphanBrimonidine may increase the antihypertensive activities of Trimethaphan.Approved, Investigational
TrimipramineBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Trimipramine.Approved
TriprolidineBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Triprolidine.Approved
UdenafilUdenafil may increase the antihypertensive activities of Brimonidine.Approved, Investigational
UnoprostoneBrimonidine may increase the antihypertensive activities of Unoprostone.Approved
UrapidilBrimonidine may increase the antihypertensive activities of Urapidil.Investigational
Valproic AcidBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Valproic Acid.Approved, Investigational
ValsartanBrimonidine may increase the antihypertensive activities of Valsartan.Approved, Investigational
VardenafilVardenafil may increase the antihypertensive activities of Brimonidine.Approved
VenlafaxineVenlafaxine may increase the tachycardic activities of Brimonidine.Approved
VeraliprideBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Veralipride.Experimental
VerapamilThe risk or severity of adverse effects can be increased when Brimonidine is combined with Verapamil.Approved
VigabatrinBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Vigabatrin.Approved
VincamineBrimonidine may increase the antihypertensive activities of Vincamine.Experimental
VinpocetineBrimonidine may increase the antihypertensive activities of Vinpocetine.Investigational
Vinyl etherBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Vinyl ether.Experimental
VortioxetineBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Vortioxetine.Approved
XenonBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Xenon.Experimental
XipamideBrimonidine may increase the antihypertensive activities of Xipamide.Experimental
XylazineBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Xylazine.Vet Approved
XylometazolineBrimonidine may increase the antihypertensive activities of Xylometazoline.Approved
YohimbineYohimbine may decrease the antihypertensive activities of Brimonidine.Approved, Vet Approved
ZaleplonBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Zaleplon.Approved, Illicit, Investigational
ZiconotideBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Ziconotide.Approved
ZimelidineThe risk or severity of adverse effects can be increased when Brimonidine is combined with Zimelidine.Withdrawn
ZiprasidoneBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Ziprasidone.Approved
ZofenoprilBrimonidine may increase the antihypertensive activities of Zofenopril.Experimental
ZolazepamBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Zolazepam.Vet Approved
ZolpidemBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.Approved
ZonisamideBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Zonisamide.Approved, Investigational
ZopicloneBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Zopiclone.Approved
ZotepineBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Zotepine.Approved, Investigational
ZuclopenthixolBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Zuclopenthixol.Approved, Investigational
Food Interactions
Not Available

References

General References
Not Available
External Links
Human Metabolome Database
HMDB14627
KEGG Drug
D02076
KEGG Compound
C07886
PubChem Compound
2435
PubChem Substance
46507305
ChemSpider
2341
BindingDB
34572
ChEBI
3175
ChEMBL
CHEMBL844
Therapeutic Targets Database
DAP000280
PharmGKB
PA448665
IUPHAR
520
Guide to Pharmacology
GtP Drug Page
RxList
RxList Drug Page
Drugs.com
Drugs.com Drug Page
Wikipedia
Brimonidine
ATC Codes
S01EA05 — BrimonidineD11AX21 — Brimonidine
AHFS Codes
  • 52:40.04 — Alpha-adrenergic Agonists
  • 84:92.00 — Misc. Skin and Mucous Membrane Agents
FDA label
Download (517 KB)
MSDS
Download (20.9 KB)

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
1CompletedPreventionIntraocular Pressure1
1CompletedScreeningHyperemia1
1CompletedTreatmentGlaucoma and Ocular Hypertension1
1RecruitingTreatmentEye Diseases / Glaucoma / Ocular Hypertension1
1, 2TerminatedTreatmentEye Dryness / Graft versus host disease in eye / Meibomian Gland Dysfunction (MGD)1
2CompletedNot AvailableMacular Degeneration / Macular Edema (ME) / Retinopathy, Diabetic1
2CompletedPreventionConjunctivitis, Seasonal Allergic1
2CompletedTreatmentAge Related Macular Degeneration (ARMD) / Retinopathy, Diabetic1
2CompletedTreatmentErythematous Rosacea1
2CompletedTreatmentGlaucoma, Primary Open Angle (POAG)1
2CompletedTreatmentGlaucoma / Ocular Hypertension1
2CompletedTreatmentOcular Hypertension / Open-angle Glaucoma (OAG)1
2CompletedTreatmentOcular Redness1
2CompletedTreatmentOpen Angle Glaucoma (OAG)1
2Not Yet RecruitingNot AvailableHealthy Volunteers1
2Not Yet RecruitingTreatmentHand-foot Syndrome1
2TerminatedTreatmentOcular Hypertension / Open-angle Glaucoma (OAG)1
2Unknown StatusTreatmentGlaucoma1
2, 3CompletedPreventionRetinopathy, Diabetic1
3CompletedNot AvailableHyperemia1
3CompletedTreatmentErythemas / Rosaceas2
3CompletedTreatmentGlaucoma, Primary Open Angle (POAG) / Ocular Hypertension1
3CompletedTreatmentGlaucoma / Ocular Hypertension4
3CompletedTreatmentHyperemia1
3CompletedTreatmentOcular Hypertension / Open-angle Glaucoma (OAG)7
3CompletedTreatmentRosaceas1
3Not Yet RecruitingTreatmentCapillary Malformations1
3Not Yet RecruitingTreatmentGlaucoma, Primary Open Angle (POAG)1
3Not Yet RecruitingTreatmentGlaucoma, Primary Open Angle (POAG) / Ocular Hypertension1
3Unknown StatusTreatmentCorneal Edema / Visual Acuity1
3Unknown StatusTreatmentGlaucoma1
4CompletedPreventionOcular Hypertension / Posterior Capsule Opacification1
4CompletedTreatmentAcne Rosacea1
4CompletedTreatmentChronic Persistent Vascular Facial Erythema1
4CompletedTreatmentGlaucoma6
4CompletedTreatmentGlaucoma, Primary Open Angle (POAG) / Ocular Hypertension1
4CompletedTreatmentGlaucoma / Ocular Hypertension5
4CompletedTreatmentOcular Hypertension / Open Angle Glaucoma (OAG)2
4CompletedTreatmentOcular Hypertension / Open-angle Glaucoma (OAG)5
4CompletedTreatmentPhysiology, Ocular / Regional Blood Flow1
4CompletedTreatmentRosaceas2
4RecruitingDiagnosticGlaucoma, Primary Open Angle (POAG) / Glaucoma; Drugs / Normal Tension Glaucoma1
4RecruitingTreatmentOcular Hypertension / Open-angle Glaucoma (OAG)2
4RecruitingTreatmentProstate Cancer1
4RecruitingTreatmentRosaceas1
4RecruitingTreatmentTelangiectasias1
4TerminatedTreatmentGlaucoma1
4TerminatedTreatmentGlaucoma, Angle-Closure1
4Unknown StatusTreatmentNormal Tension Glaucoma1
4WithdrawnSupportive CareRelapsing Remitting Multiple Sclerosis (RRMS)1
Not AvailableCompletedNot AvailableHealthy Volunteers1
Not AvailableCompletedNot AvailableOcular Hypertension / Open-angle Glaucoma (OAG)1
Not AvailableCompletedNot AvailableRosaceas1
Not AvailableCompletedBasic ScienceGlaucoma1
Not AvailableCompletedOtherRosaceas1
Not AvailableCompletedPreventionIntraocular Pressure Change in Intravitreal Injection1
Not AvailableCompletedTreatmentGlaucoma1
Not AvailableCompletedTreatmentGlaucoma / Ocular Hypertension2
Not AvailableCompletedTreatmentOcular Hypertension / Open Angle Glaucoma (OAG) / Pseudoexfoliation Syndrome1
Not AvailableCompletedTreatmentPhysiology, Ocular / Retina1
Not AvailableCompletedTreatmentPrimary Vascular Dysregulation1
Not AvailableNot Yet RecruitingPreventionOcular Hypertension1
Not AvailableRecruitingTreatmentComplications of Diabetes Mellitus1
Not AvailableUnknown StatusNot AvailableImpact of Brimonidine on the Cornea1
Not AvailableUnknown StatusTreatmentGlaucoma / Ocular Hypertension1
Not AvailableUnknown StatusTreatmentIntraocular Pressure1
Not AvailableWithdrawnBasic ScienceGlaucoma1
Not AvailableWithdrawnDiagnosticIntraocular Pressure / Physiology, Ocular1

Pharmacoeconomics

Manufacturers
  • Allergan inc
  • Allergan
  • Akorn inc
  • Alcon inc
  • Alcon research ltd
  • Bausch and lomb pharmaceuticals inc
  • Sandoz canada inc
  • Teva parenteral medicines inc
  • Allergan, Inc
Packagers
Dosage forms
FormRouteStrength
LiquidOphthalmic0.2 %
SolutionOphthalmic0.15 %
Solution / dropsOphthalmic1 mg/mL
Solution / dropsOphthalmic1.5 mg/mL
SolutionOphthalmic1.5 mg/mL
SolutionOphthalmic2 mg/mL
Solution / dropsOphthalmic2 mg/mg
Solution / dropsOphthalmic2 mg/mL
SolutionOphthalmic
Solution / dropsOphthalmic
GelCutaneous3 mg/g
GelTopical5 mg/g
GelTopical0.33 %
SolutionOphthalmic0.2 %
SuspensionOphthalmic
Suspension / dropsOphthalmic
Prices
Unit descriptionCostUnit
Alphagan P 15ml Bottle .15% 15ml Bottle228.5USD bottle
Brimonidine Tartrate 0.15% Solution 15ml Bottle218.5USD bottle
Alphagan P 0.1% Solution 15ml Bottle208.94USD bottle
Alphagan P 10ml Bottle .15% 10ml Bottle152.32USD bottle
Brimonidine Tartrate 0.15% Solution 10ml Bottle145.65USD bottle
Alphagan P 0.1% Solution 10ml Bottle143.97USD bottle
Alphagan P 5ml Bottle .15% 5ml Bottle79.52USD bottle
Brimonidine Tartrate 0.15% Solution 5ml Bottle72.85USD bottle
Brimonidine Tartrate 0.2% Solution 10ml Bottle67.85USD bottle
Brimonidine Tartrate 0.2% Solution 15ml Bottle56.88USD bottle
Brimonidine Tartrate 0.2% Solution 5ml Bottle33.96USD bottle
Brimonidine tartrate 0.15% drp29.82USD ml
Alphagan p 0.15% eye drops14.65USD ml
Alphagan p 0.1% drops13.85USD ml
Brimonidine 0.2% eye drop6.53USD ml
Alphagan 0.2 % Solution3.72USD ml
Apo-Brimonidine 0.2 % Solution2.08USD ml
Pms-Brimonidine 0.2 % Solution2.08USD ml
Ratio-Brimonidine 0.2 % Solution2.08USD ml
Sandoz Brimonidine 0.2 % Solution2.08USD ml
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
Patent NumberPediatric ExtensionApprovedExpires (estimated)
US5424078No1995-06-132012-06-13Us
CA2173974No2006-05-022014-09-19Canada
CA2225626No2002-09-032016-06-17Canada
US9295641Yes2002-01-102022-01-10Us
US6627210Yes2002-01-182022-01-18Us
US6673337Yes2002-01-262022-01-26Us
US6562873Yes2002-01-102022-01-10Us
US6641834Yes2002-01-282022-01-28Us
US7030149No2002-04-192022-04-19Us
US7320976No2002-04-192022-04-19Us
US7642258No2002-04-192022-04-19Us
US8133890No2002-04-192022-04-19Us
US8354409No2002-04-192022-04-19Us
US8748425No2002-04-192022-04-19Us
US7323463No2003-01-192023-01-19Us
US7265117No2005-08-192025-08-19Us
US8858961Yes2004-03-022024-03-02Us
US6316441No1999-12-072019-12-07Us
US9044484No2010-10-302030-10-30Us
US8410102No2005-05-242025-05-24Us
US8053427No2011-06-132031-06-13Us
US7439241No2005-08-252025-08-25Us
US8513247No2011-03-252031-03-25Us
US8426410No2005-05-242025-05-24Us
US8513249No2011-03-252031-03-25Us
US8859551No2004-05-252024-05-25Us
US8231885No2005-05-242025-05-24Us
US8163725No2011-06-132031-06-13Us
US9474751No2002-04-192022-04-19Us
US9687443No2001-07-102021-07-10Us
US9421265No2010-06-172030-06-17Us
US9770453No2002-04-192022-04-19Us

Properties

State
Solid
Experimental Properties
PropertyValueSource
melting point (°C)207.5 °CNot Available
water solubilitySoluble (1.5 mg/mL)Not Available
logP1.7Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.154 mg/mLALOGPS
logP1.27ALOGPS
logP1.37ChemAxon
logS-3.3ALOGPS
pKa (Strongest Basic)8.32ChemAxon
Physiological Charge1ChemAxon
Hydrogen Acceptor Count5ChemAxon
Hydrogen Donor Count2ChemAxon
Polar Surface Area62.2 Å2ChemAxon
Rotatable Bond Count1ChemAxon
Refractivity68.49 m3·mol-1ChemAxon
Polarizability25.74 Å3ChemAxon
Number of Rings3ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.978
Blood Brain Barrier+0.717
Caco-2 permeable+0.5435
P-glycoprotein substrateSubstrate0.7017
P-glycoprotein inhibitor INon-inhibitor0.5688
P-glycoprotein inhibitor IIInhibitor0.5951
Renal organic cation transporterInhibitor0.8266
CYP450 2C9 substrateNon-substrate0.8403
CYP450 2D6 substrateNon-substrate0.7533
CYP450 3A4 substrateNon-substrate0.5617
CYP450 1A2 substrateNon-inhibitor0.9046
CYP450 2C9 inhibitorNon-inhibitor0.9071
CYP450 2D6 inhibitorNon-inhibitor0.9231
CYP450 2C19 inhibitorNon-inhibitor0.9025
CYP450 3A4 inhibitorInhibitor0.6898
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.7044
Ames testNon AMES toxic0.8222
CarcinogenicityNon-carcinogens0.9446
BiodegradationNot ready biodegradable1.0
Rat acute toxicity3.0196 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.8093
hERG inhibition (predictor II)Non-inhibitor0.6711
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397)

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted GC-MS Spectrum - GC-MSPredicted GC-MSNot Available
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available
MS/MS Spectrum - , positiveLC-MS/MSsplash10-0006-0190000000-49c10e93a1977cbe01da

Taxonomy

Description
This compound belongs to the class of organic compounds known as quinoxalines. These are compounds containing a quinoxaline moiety, a bicyclic heterocycle made up of a benzene ring fused to a pyrazine ring.
Kingdom
Organic compounds
Super Class
Organoheterocyclic compounds
Class
Diazanaphthalenes
Sub Class
Benzodiazines
Direct Parent
Quinoxalines
Alternative Parents
Pyrazines / Benzenoids / Aryl bromides / Imidazolines / Heteroaromatic compounds / Guanidines / Propargyl-type 1,3-dipolar organic compounds / Carboximidamides / Azacyclic compounds / Organopnictogen compounds
show 2 more
Substituents
Quinoxaline / Aryl bromide / Aryl halide / Pyrazine / Benzenoid / 2-imidazoline / Heteroaromatic compound / Guanidine / Azacycle / Carboximidamide
show 9 more
Molecular Framework
Aromatic heteropolycyclic compounds
External Descriptors
imidazoles, quinoxaline derivative, secondary amine (CHEBI:3175)

Targets

Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Agonist
General Function
Thioesterase binding
Specific Function
Alpha-2 adrenergic receptors mediate the catecholamine-induced inhibition of adenylate cyclase through the action of G proteins. The rank order of potency for agonists of this receptor is oxymetazo...
Gene Name
ADRA2A
Uniprot ID
P08913
Uniprot Name
Alpha-2A adrenergic receptor
Molecular Weight
48956.275 Da
References
  1. Rauly I, Ailhaud M, Wurch T, Pauwels PJ: alpha(2A)-adrenoceptor: G(alphai1) protein-mediated pertussis toxin-resistant attenuation of G(s) coupling to the cyclic AMP pathway. Biochem Pharmacol. 2000 Jun 15;59(12):1531-8. [PubMed:10799649]
  2. Wikberg-Matsson A, Simonsen U: Potent alpha(2A)-adrenoceptor-mediated vasoconstriction by brimonidine in porcine ciliary arteries. Invest Ophthalmol Vis Sci. 2001 Aug;42(9):2049-55. [PubMed:11481271]
  3. Meana JJ, Barturen F, Garro MA, Garcia-Sevilla JA, Fontan A, Zarranz JJ: Decreased density of presynaptic alpha 2-adrenoceptors in postmortem brains of patients with Alzheimer's disease. J Neurochem. 1992 May;58(5):1896-904. [PubMed:1373179]
  4. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352]
Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Agonist
General Function
Epinephrine binding
Specific Function
Alpha-2 adrenergic receptors mediate the catecholamine-induced inhibition of adenylate cyclase through the action of G proteins. The rank order of potency for agonists of this receptor is clonidine...
Gene Name
ADRA2B
Uniprot ID
P18089
Uniprot Name
Alpha-2B adrenergic receptor
Molecular Weight
49565.8 Da
References
  1. Trendelenburg AU, Philipp M, Meyer A, Klebroff W, Hein L, Starke K: All three alpha2-adrenoceptor types serve as autoreceptors in postganglionic sympathetic neurons. Naunyn Schmiedebergs Arch Pharmacol. 2003 Dec;368(6):504-12. Epub 2003 Nov 11. [PubMed:14610637]
  2. Bohmann C, Schollmeyer P, Rump LC: Methoxamine inhibits noradrenaline release through activation of alpha 1- and alpha 2-adrenoceptors in rat isolated kidney: involvement of purines and prostaglandins. Naunyn Schmiedebergs Arch Pharmacol. 1993 Mar;347(3):273-9. [PubMed:8097565]
Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Agonist
General Function
Protein homodimerization activity
Specific Function
Alpha-2 adrenergic receptors mediate the catecholamine-induced inhibition of adenylate cyclase through the action of G proteins.
Gene Name
ADRA2C
Uniprot ID
P18825
Uniprot Name
Alpha-2C adrenergic receptor
Molecular Weight
49521.585 Da
References
  1. Trendelenburg AU, Philipp M, Meyer A, Klebroff W, Hein L, Starke K: All three alpha2-adrenoceptor types serve as autoreceptors in postganglionic sympathetic neurons. Naunyn Schmiedebergs Arch Pharmacol. 2003 Dec;368(6):504-12. Epub 2003 Nov 11. [PubMed:14610637]
  2. Orito K, Kishi M, Imaizumi T, Nakazawa T, Hashimoto A, Mori T, Kambe T: alpha(2)-adrenoceptor antagonist properties of OPC-28326, a novel selective peripheral vasodilator. Br J Pharmacol. 2001 Oct;134(4):763-70. [PubMed:11606316]
  3. Zhang W, Ordway GA: The alpha2C-adrenoceptor modulates GABA release in mouse striatum. Brain Res Mol Brain Res. 2003 Apr 10;112(1-2):24-32. [PubMed:12670699]
  4. Prinster SC, Holmqvist TG, Hall RA: Alpha2C-adrenergic receptors exhibit enhanced surface expression and signaling upon association with beta2-adrenergic receptors. J Pharmacol Exp Ther. 2006 Sep;318(3):974-81. Epub 2006 Jun 6. [PubMed:16757535]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Xanthine dehydrogenase activity
Specific Function
Oxidase with broad substrate specificity, oxidizing aromatic azaheterocycles, such as N1-methylnicotinamide and N-methylphthalazinium, as well as aldehydes, such as benzaldehyde, retinal, pyridoxal...
Gene Name
AOX1
Uniprot ID
Q06278
Uniprot Name
Aldehyde oxidase
Molecular Weight
147916.735 Da
References
  1. Acheampong AA, Chien DS, Lam S, Vekich S, Breau A, Usansky J, Harcourt D, Munk SA, Nguyen H, Garst M, Tang-Liu D: Characterization of brimonidine metabolism with rat, rabbit, dog, monkey and human liver fractions and rabbit liver aldehyde oxidase. Xenobiotica. 1996 Oct;26(10):1035-55. [PubMed:8905918]

Drug created on June 13, 2005 07:24 / Updated on December 10, 2017 17:18